Roni Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2025650/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Myocardial efficiency in patients with different aetiologies and stages of heart failure. European Heart Journal Cardiovascular Imaging, 2022, 23, 328-337.	1.2	8
2	Clinical use of cardiac 18ÂF-FDG viability PET: a retrospective study of 44 patients undergoing post-test revascularization. International Journal of Cardiovascular Imaging, 2022, 38, 2447-2458.	0.6	1
3	The impact of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	4.4	16
4	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
5	Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation, 2019, 139, 2129-2141.	1.6	289
6	Effect of Blood Flow Restricted Resistance Exercise and Remote Ischemic Conditioning on Functional Capacity and Myocellular Adaptations in Patients With Heart Failure. Circulation: Heart Failure, 2019, 12, e006427.	3.9	33
7	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	2.1	18
8	Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure. Pulmonary Circulation, 2018, 8, 1-7.	1.7	6
9	Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. Journal of Nuclear Cardiology, 2018, 25, 169-176.	2.1	32
10	Test–retest repeatability of myocardial oxidative metabolism and efficiency using standalone dynamic 11C-acetate PET and multimodality approaches in healthy controls. Journal of Nuclear Cardiology, 2018, 25, 1929-1936.	2.1	15
11	Myocardial Oxygen Consumption and Efficiency in Aortic Valve Stenosis Patients With and Without Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	24
12	Ketone Body Infusion With 3â€Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. Journal of the American Heart Association, 2017, 6, .	3.7	144
13	Metoprolol Reduces Hemodynamic and Metabolic Overload in Asymptomatic Aortic Valve Stenosis Patients. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	32
14	Effect of liraglutide, a glucagonâ€like peptideâ€1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)—a multicentre, doubleâ€blind, randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	7.1	343
15	Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. BMJ Open Diabetes Research and Care, 2016, 4, e000202.	2.8	13
16	A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQqO	0 0 r g ®T /O	verback 10 Tf
	Failing Heart of Patients With Type 2 Diabetes Mellitus Can Adapt to Extreme Short-term Increases in		

17	Failing Heart of Patients With Type 2 Diabetes Mellitus Can Adapt to Extreme Short-term Increases in Circulating Lipids and Does Not Display Features of Acute Myocardial Lipotoxicity. Circulation: Heart Failure, 2013, 6, 845-852.	3.9	20
18	Effect of Acute Hyperglycemia on Left Ventricular Contractile Function in Diabetic Patients with and without Heart Failure: Two Randomized Cross-Over Studies. PLoS ONE, 2013, 8, e53247.	2.5	17

#	Article	IF	CITATIONS
19	Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1220-H1225.	3.2	34